血清睾酮与前列腺癌关系的研究进展
Research Progress on the Relationship between Serum Testosterone and Prostate Cancer
DOI: 10.12677/ACM.2023.13122836, PDF,    科研立项经费支持
作者: 卓 涛, 王玉杰, 安恒庆：新疆医科大学第一附属医院泌尿外科，新疆 乌鲁木齐
关键词: 前列腺癌；睾酮；睾酮替代疗法；Prostate Cancer； Testosterone； Testosterone Replacement Therapy
摘要: 前列腺癌(Prostate Cancer, PCa)发病率在我国呈上升趋势，睾酮与PCa密切相关。过去认为高的血清睾酮是PCa的促进因素，但这一观点正在被逐渐打破，更多的研究发现治疗前低的血清睾酮水平是PCa的危险因素，并且接受睾酮替代疗法(Testosterone Replacement Therapy, TRT)似乎不会增加PCa发生和复发风险。本文对低、高血清睾酮水平以及TRT治疗与PCa关系的研究进行了综述。
Abstract: The incidence of prostate cancer (PCa) is increasing in my country, and there is a close association between PCa and testosterone. Previously, it was believed that high levels of serum testosterone promoted PCa, but this belief is gradually being challenged. Recent studies have shown that low levels of serum testosterone before treatment are actually a risk factor for PCa. Furthermore, it has been found that receiving testosterone replacement therapy (TRT) does not increase the risk of developing or recurring PCa. This article provides a comprehensive review of the research on the relationship between low and high levels of serum testosterone, TRT treatment, and PCa.
文章引用：卓涛, 王玉杰, 安恒庆. 血清睾酮与前列腺癌关系的研究进展 [J]. 临床医学进展, 2023, 13(12): 20150-20154. https://doi.org/10.12677/ACM.2023.13122836

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D., Wagle, N.S., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[3] Goldman, A.L., Bhasin, S., Wu, F.C.W., et al. (2017) A Reappraisal of Testosterone’s Binding in Circulation: Physiological and Clinical Implications. Endocrine Reviews, 38, 302-324. [Google Scholar] [CrossRef] [PubMed]
[4] Geniole, S.N. and Car-ré, J.M. (2018) Human Social Neuroendocrinology: Review of the Rapid Effects of Testosterone. Hormones and Be-havior, 104, 192-205. [Google Scholar] [CrossRef] [PubMed]
[5] Cunningham, G.R., Stephens-Shields, A.J., Rosen, R.C., et al. (2015) Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials. The Journal of Clinical Endocrinology & Metabolism, 100, 1146-1155. [Google Scholar] [CrossRef] [PubMed]
[6] Zhu, A., Andino, J., Daignault-Newton, S., et al. (2022) What Is a Nor-mal Testosterone Level for Young Men? Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20-44 Years Old. Journal of Urology, 208, 1295-1302. [Google Scholar] [CrossRef] 
[7] Kutlikova, H.H., Durdiaková, J.B., Wagner, B., et al. (2020) The Effects of Testosterone on the Physiological Response to Social and Somatic Stressors. Psychoneuroendocrinology, 117, Article ID: 104693. [Google Scholar] [CrossRef] [PubMed]
[8] Mchenry, J., Carrier, N., Hull, E. and Kabbaj, M. (2014) Sex Differences in Anxiety and Depression: Role of Testosterone. Frontiers in Neuroendocrinology, 35, 42-57. [Google Scholar] [CrossRef] [PubMed]
[9] Welén, K. and Damber, J.E. (2022) Androgens, Aging, and Pros-tate Health. Reviews in Endocrine and Metabolic Disorders, 23, 1221-1231. [Google Scholar] [CrossRef] [PubMed]
[10] Desai, K., Mcmanus, J.M. and Sharifi, N. (2021) Hormonal Therapy for Prostate Cancer. Endocrine Reviews, 42, 354-373. [Google Scholar] [CrossRef] [PubMed]
[11] Morgentaler, A., Bruning III, C.O. and Dewolf, W.C. (1996) Occult Prostate Cancer in Men with Low Serum Testosterone Levels. JAMA, 276, 1904-1906. [Google Scholar] [CrossRef] [PubMed]
[12] Morgentaler, A. and Rhoden, E.L. (2006) Prevalence of Prostate Cancer among Hypogonadal Men with Prostate-Specific Antigen Levels of 4.0 ng/mL or Less. Urology, 68, 1263-1267. [Google Scholar] [CrossRef] [PubMed]
[13] Shin, B.S., Hwang, E.C., Im, C.M., et al. (2010) Is a De-creased Serum Testosterone Level a Risk Factor for Prostate Cancer? A Cohort Study of Korean Men. Korean Journal of Urology, 51, 819-823. [Google Scholar] [CrossRef] [PubMed]
[14] Gao, Y., Jiang, C.Y., Mao, S.K., et al. (2016) Low Serum Testos-terone Predicts Upgrading and Upstaging of Prostate Cancer after Radical Prostatectomy. Asian Journal of Andrology, 18, 639-643. [Google Scholar] [CrossRef] 
[15] Røder, M.A., Christensen, I.J., Berg, K.D., et al. (2012) Serum Testosterone Level as a Predictor of Biochemical Failure after Radical Prostatectomy for Localized Prostate Cancer. BJU International, 109, 520-524. [Google Scholar] [CrossRef] 
[16] Dai, B., Qu, Y., Kong, Y., et al. (2012) Low Pretreatment Serum Total Testosterone Is Associated with a High Incidence of Gleason Score 8-10 Disease in Prostatectomy Speci-mens: Data from Ethnic Chinese Patients with Localized Prostate Cancer. BJU International, 110, E667-E672. [Google Scholar] [CrossRef] 
[17] Massengill, J.C., Sun, L., Moul, J.W., et al. (2003) Pre-treatment Total Testosterone Level Predicts Pathological Stage in Patients with Localized Prostate Cancer Treated with Radical Prostatectomy. Journal of Urology, 169, 1670-1675. [Google Scholar] [CrossRef] [PubMed]
[18] Gann, P.H., Hennekens, C.H., Ma, J., et al. (1996) Pro-spective Study of Sex Hormone Levels and Risk of Prostate Cancer. Journal of the National Cancer Institute, 88, 1118-1126. [Google Scholar] [CrossRef] [PubMed]
[19] Shaneyfelt, T., Husein, R., Bubley, G. and Mantzoros, C.S. (2000) Hormonal Predictors of Prostate Cancer: A Meta-Analysis. Journal of Clinical Oncology, 18, 847-853. [Google Scholar] [CrossRef] 
[20] Platz, E.A., Leitzmann, M.F., Rifai, N., et al. (2005) Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Pros-tate-Specific Antigen Era. Cancer Epidemiology, Biomarkers & Prevention, 14, 1262-1269. [Google Scholar] [CrossRef] 
[21] Porcaro, A.B., Petroziello, A., Brunelli, M., et al. (2016) High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy. Urologia Internationalis, 96, 470-478. [Google Scholar] [CrossRef] [PubMed]
[22] Salonia, A., Abdollah, F., Capitanio, U., et al. (2013) Preoperative Sex Steroids Are Significant Predictors of Early Biochemical Recurrence after Radical Prostatectomy. World Journal of Urology, 31, 275-280. [Google Scholar] [CrossRef] [PubMed]
[23] Yamamoto, S., Yonese, J., Kawakami, S., et al. (2007) Preopera-tive Serum Testosterone Level as an Independent Predictor of Treatment Failure following Radical Prostatectomy. Euro-pean Urology, 52, 696-701. [Google Scholar] [CrossRef] [PubMed]
[24] Ahmadi, H., Allameh, F., Baradaran, N., et al. (2011) Circulating Sex Hormones Play No Role in the Association between Sexual Activity and the Risk of Prostate Cancer. The Journal of Sexual Medicine, 8, 905-913. [Google Scholar] [CrossRef] [PubMed]
[25] Morales, A. and Siemens, D.R. (2022) Testosterone Ther-apy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations. Urologic Clinics of North America, 49, 573-582. [Google Scholar] [CrossRef] [PubMed]
[26] Haider, A., Zitzmann, M., Doros, G., et al. (2015) Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries. Journal of Urology, 193, 80-86. [Google Scholar] [CrossRef] [PubMed]
[27] Khera, M., Crawford, D., Morales, A., et al. (2014) A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications. European Urology, 65, 115-123. [Google Scholar] [CrossRef] [PubMed]
[28] Kaplan, A.L., Trinh, Q.D., Sun, M., et al. (2014) Testosterone Replacement Therapy following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends. The Journal of Sex-ual Medicine, 11, 1063-1070. [Google Scholar] [CrossRef] [PubMed]
[29] Pastuszak, A.W., Pearlman, A.M., Lai, W.S., et al. (2013) Testosterone Replacement Therapy in Patients with Prostate Cancer after Radical Prostatectomy. Journal of Urology, 190, 639-644. [Google Scholar] [CrossRef] [PubMed]
[30] Leibowitz, R.L., Dorff, T.B., Tucker, S., et al. (2010) Testosterone Replacement in Prostate Cancer Survivors with Hypogonadal Symptoms. BJU International, 105, 1397-1401. [Google Scholar] [CrossRef] 
[31] Lenfant, L., Leon, P., Cancel-Tassin, G., et al. (2020) Testosterone Replacement Therapy (TRT) and Prostate Cancer: An Updated Systematic Review with a Focus on Previ-ous or Active Localized Prostate Cancer. Urologic Oncology: Seminars and Original Investigations, 38, 661-670. [Google Scholar] [CrossRef] [PubMed]
[32] Kaplan, A.L., Hu, J.C., Morgentaler, A., et al. (2016) Testos-terone Therapy in Men with Prostate Cancer. European Urology, 69, 894-903. [Google Scholar] [CrossRef] [PubMed]
[33] Kumar, R., Sena, L.A., Denmeade, S.R. and Kachhap, S. (2023) The Testosterone Paradox of Advanced Prostate Cancer: Mechanistic Insights and Clinical Implications. Nature Reviews Urology, 20, 265-278. [Google Scholar] [CrossRef] [PubMed]

为你推荐